Candel Therapeutics, Inc.

NasdaqGM:CADL Stock Report

Market Cap: US$143.4m

Candel Therapeutics Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Candel Therapeutics.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth27.4%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Candel Therapeutics: Innovative Cancer Therapies, But Short Cash Runway

Jul 01

Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer

Apr 15

Candel gets European orphan drug designation for brain, spinal cord tumor treatment

Sep 15

Candel Therapeutics appoints CFO, chief medical officer

Sep 07

Candel Therapeutics: Next-Generation Oncolytic Viral Immunotherapies

Oct 21

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Candel Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqGM:CADL - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/2024N/A-50-31-31N/A
3/31/2024N/A-37-32-32N/A
12/31/2023N/A-38-35-34N/A
9/30/20230-32-34-34N/A
6/30/20230-32-35-34N/A
3/31/20230-27-35-34N/A
12/31/20220-19-33-31N/A
9/30/20220-12-31-30N/A
6/30/20220-20-29-27N/A
3/31/20220-33-26-25N/A
12/31/20210-36-24-22N/A
9/30/20210-48-22-20N/A
6/30/20210-35-17-15N/A
3/31/20210-20-14-12N/A
12/31/20200-18-11-9N/A
12/31/20190-8-5-5N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if CADL's forecast earnings growth is above the savings rate (2.6%).

Earnings vs Market: Insufficient data to determine if CADL's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if CADL's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if CADL's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if CADL's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CADL's Return on Equity is forecast to be high in 3 years time


Discover growth companies